For example, in breast cancer, NAT1 expression is downregulated in young patients (≤45 years) compared with that in old patients (36), whereas NTA1 presents overexpressed in estrogen receptor-positive cancer in comparison of estrogen receptor-negative cancer (29). This evidence concerns the gene ESR1 and breast carcinoma.